Kokarboksilazu hydrochloride

When ATH:
A11DA

Pharmacological action

Kokarboksilazu is a coenzyme of enzymes, involved in carbohydrate metabolism (a part of the carboxylase, catalyzes the decarboxylation of alpha-keto acids).

Exogenous Vitamin B1 (thiamine) to participate in these processes must be metabolized by phosphorylation in kokarboksilazu. Thus, kokarboksilaza a finished form of coenzyme, formed from thiamine during its conversion in the body. Note, that the property is only partially adequate cocarboxylase that of thiamine; kokarboksilazu not used for the prevention and treatment of hypo- B1 and beriberi.

Pharmacokinetics

Kokarboksilazu rapidly absorbed after intramuscular administration. It penetrates into most tissues of the body. Undergoes metabolic degradation. The metabolic products excreted primarily by the kidneys.

Testimony

Kokarboksilazu prescribed in the treatment of liver and kidney failure, diabetic precoma and coma, diabeticheskogo ketoacidosis, chronic cardiovascular disease and cardiac arrhythmias, peripheral neuritis.

Babies drug prescribed for the same indications. Newborn drug is also used in the treatment of conditions, associated with hypoxia and acidosis, including neonatal asphyxia, hypoxic encephalopathy, circulatory failure, pneumonia, sepsis and other diseases.

Dosage regimen

Kokarboksilazu hydrochloride is administered intramuscularly or intravenously (bolus or infusion). The contents of the ampule (0,025 or 0,05 g) dissolved directly before introduction into 2 ml water for injection. When intravenously administered volume adjusted to 10-20 ml, under drip - up to 200-400 ml, adding isotonic sodium chloride or glucose solution.

Dose set individually, depending on the nature and severity of the disease state of the patient.

In diseases of the heart appoint 0.1-0.2 g per day for 15-30 days. In acute renal and liver failure is administered intravenously (of 0.1-0.15 g 3 once a day) or drip (on 5% glucose solution - at 0.1-0.15 g per day). When peripheral neuritis administered intramuscularly at a dose of 0.05-0.1 g per day for 1-1.5 months. In diabetic coma if necessary medicament is administered initially at a dose of 50-100 mg, then allowed reintroduction of 1-2 hours; later moving to a maintenance dose - 50 mg per day. When circulatory failure, the drug is administered at a dose of 50 mg for 2 hours before use of digitalis preparations 2-3 times a day.

Children injected intramuscularly, intravenously (drip or stream). Depending on the severity of clinical symptoms and prescribed by 25 mg 50 mg per day. The course of treatment from 3-7 up to 15-30 days. Newborns administered intravenously (slowly) 10 mg 1 kg of body weight once a day.

Cautions

In diabetes (Acidosis, coma) It can be applied in a daily dose of up to 1 g (1000 mg).

Side effect

Allergic reactions (hives, itch), intramuscular injection - redness, itch, swelling at the injection site.

Contraindications

Hypersensitivity to the drug.

Drug Interactions

There is information on enhancing cocarboxylase during concomitant use of cytochrome C, lipoic acid, drugs pantothenic acid. Cocarboxylase enhances the effect of cardiac glycosides and improves portability.

Overdose

No cases of overdose cocarboxylase not reported.